Geoffrey von Maltzahn, Flagship General Partner and co-founder & CEO of Flagship-founded Tessera Therapeutics, explains Tessera's novel gene writing bioplatform and its vast potential for preventing and curing disease.
More from:
Human Health,
Sustainability

What If We Could See Disease Coming and Stop It?

Amanda Kay on a New Approach to Biopharma Partnerships

Pioneering Partnerships: Advancing a Portfolio of Novel Medicines and Vaccines with GSK

Pioneering Partnerships: Accelerating our Collaboration with Pfizer

Unlocking Therapeutic Breakthroughs with the Power of Platform Technologies
